Literature DB >> 2884392

Verapamil inhibits cyclosporin metabolism.

A Lindholm, S Henricsson.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1987        PMID： 2884392     DOI： 10.1016/s0140-6736(87)92710-3

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  18 in total

Review 1.  Pharmacokinetic drug interactions with cyclosporin (Part II).

Authors:  G C Yee; T R McGuire
Journal:  Clin Pharmacokinet       Date:  1990-11       Impact factor: 6.447

Review 2.  Pharmacokinetic interactions with calcium channel antagonists (Part II).

Authors:  K D Schlanz; S A Myre; M B Bottorff
Journal:  Clin Pharmacokinet       Date:  1991-12       Impact factor: 6.447

Review 3.  Clinically significant drug interactions with cyclosporin. An update.

Authors:  C Campana; M B Regazzi; I Buggia; M Molinaro
Journal:  Clin Pharmacokinet       Date:  1996-02       Impact factor: 6.447

4.  The effect of combined therapy on the pharmacokinetics and pharmacodynamics of verapamil and propranolol in patients with angina pectoris.

Authors:  J C McCourty; J H Silas; G T Tucker; M S Lennard
Journal:  Br J Clin Pharmacol       Date:  1988-03       Impact factor: 4.335

5.  Influence of nicardipine on renal function and plasma cyclosporin in renal transplant patients.

Authors:  M Kessler; P Netter; E Renoult; B Jonon; J M Mur; P Trechot; B Dousset
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

Review 6.  Calcium antagonists. Drug interactions of clinical significance.

Authors:  T Rosenthal; D Ezra
Journal:  Drug Saf       Date:  1995-09       Impact factor: 5.606

Review 7.  Verapamil. An updated review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension.

Authors:  D McTavish; E M Sorkin
Journal:  Drugs       Date:  1989-07       Impact factor: 9.546

Review 8.  The use of other drugs to allow a lower dosage of cyclosporin to be used. Therapeutic and pharmacoeconomic considerations.

Authors:  T E Jones
Journal:  Clin Pharmacokinet       Date:  1997-05       Impact factor: 6.447

9.  Nifedipine, verapamil and cyclosporin A pharmacokinetics in children.

Authors:  M R Ogborn; J F Crocker; P C Grimm
Journal:  Pediatr Nephrol       Date:  1989-07       Impact factor: 3.714

10.  Identification of P450 enzymes involved in metabolism of verapamil in humans.

Authors:  H K Kroemer; J C Gautier; P Beaune; C Henderson; C R Wolf; M Eichelbaum
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1993-09       Impact factor: 3.000
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.